These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29403323)

  • 1. Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma.
    Nomura S; Ito T; Yoshimura H; Hotta M; Nakanishi T; Fujita S; Nakaya A; Satake A; Ishii K
    J Blood Med; 2018; 9():1-7. PubMed ID: 29403323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet-Derived Microparticles are an Important Biomarker in Patients with Cancer-Associated Thrombosis.
    Yamanaka Y; Sawai Y; Nomura S
    Int J Gen Med; 2019; 12():491-497. PubMed ID: 32099444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer.
    Niki M; Yokoi T; Kurata T; Nomura S
    Lung Cancer (Auckl); 2017; 8():91-99. PubMed ID: 28814907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment.
    Garrison LP; Wang ST; Huang H; Ba-Mancini A; Shi H; Chen K; Korves C; Dhawan R; Cakana A; van de Velde H; Corzo D; Duh MS
    Oncologist; 2013; 18(1):27-36. PubMed ID: 23299777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased serum vWF and sVCAM-1 levels are associated with late or very late angiographic stent thrombosis after sirolimus-eluting stent implantation.
    Jin C; Lu L; Zhu ZB; Zhang RY; Zhang Q; Du R; Ding FH; Chen QJ; Shen WF
    Coron Artery Dis; 2010 Aug; 21(5):273-7. PubMed ID: 20508517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis.
    Okuda Y; Omoto S; Taniura T; Shouzu A; Nomura S
    Int J Gen Med; 2016; 9():65-71. PubMed ID: 27110135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.
    Helley D; de Latour RP; Porcher R; Rodrigues CA; Galy-Fauroux I; Matheron J; Duval A; Schved JF; Fischer AM; Socié G;
    Haematologica; 2010 Apr; 95(4):574-81. PubMed ID: 20081060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
    Zangari M; Fink L; Zhan F; Tricot G
    Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):228-36. PubMed ID: 21575928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of thrombosis.
    Kaplanski G; Cacoub P; Farnarier C; Marin V; Grégoire R; Gatel A; Durand JM; Harlé JR; Bongrand P; Piette JC
    Arthritis Rheum; 2000 Jan; 43(1):55-64. PubMed ID: 10643700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database.
    Jimenez-Zepeda VH; Venner C; McCurdy A; Masih-Khan E; Atenafu EG; Sebag M; Stakiw J; Song K; LeBlanc R; Reiman T; Louzada M; Kotb R; Gul E; Reece D
    Br J Haematol; 2021 May; 193(3):532-541. PubMed ID: 33559897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of an ELISA kit for platelet-derived microparticles by joint research at many institutes in Japan.
    Nomura S; Shouzu A; Taomoto K; Togane Y; Goto S; Ozaki Y; Uchiyama S; Ikeda Y
    J Atheroscler Thromb; 2009; 16(6):878-87. PubMed ID: 20032575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
    Mateos MV; Richardson PG; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Esseltine DL; Liu K; Cakana A; van de Velde H; San Miguel JF
    J Clin Oncol; 2010 May; 28(13):2259-66. PubMed ID: 20368561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Thrombotic complications following the treatment of multiple myeloma with new agents].
    Rupa-Matysek J; Gil L; Komarnicki M
    Pol Merkur Lekarski; 2011 Dec; 31(186):372-7. PubMed ID: 22239010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microvesicles shed from bortezomib-treated or lenalidomide-treated human myeloma cells inhibit angiogenesis in vitro.
    Guo HM; Sun L; Yang L; Liu XJ; Nie ZY; Luo JM
    Oncol Rep; 2018 Jun; 39(6):2873-2880. PubMed ID: 29693175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
    Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
    Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenic markers in plasma cell myeloma patients treated with novel agents.
    Medinger M; Halter J; Heim D; Buser A; Gerull S; Stern M; Passweg J
    Anticancer Res; 2015 Feb; 35(2):1085-90. PubMed ID: 25667497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
    Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
    Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
    Nijhof IS; Groen RW; Noort WA; van Kessel B; de Jong-Korlaar R; Bakker J; van Bueren JJ; Parren PW; Lokhorst HM; van de Donk NW; Martens AC; Mutis T
    Clin Cancer Res; 2015 Jun; 21(12):2802-10. PubMed ID: 25398450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of pitavastatin on plasminogen activator inhibitor-1 in hyperlipidemic patients.
    Nomura S; Taniura T; Shouzu A; Omoto S; Inami N; Fujita S; Tamaki T; Yokoi T; Shimizu T; Ito T
    Int J Gen Med; 2012; 5():535-40. PubMed ID: 22807641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.